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Introduction 
 
The therapeutic value of metal-based drug com-
pounds has been established for almost a cen-
tury [1-5]. Cisplatin is the typical example of 
metal compounds being widely used in patients 
as an anti-cancer agent. Gold(III) is isoelectronic 
with platinum (II) and four coordinate gold(III) 
complexes also adopt a square-planar geometry 
as cisplatin [6, 7]. In fact, the potent tumor-
suppressive effects of gold(III) complexes have 
been demonstrated in a wide range of cancer 
cells  and animal models [8-16].   
 
Gold-2a [5-hydroxyphenyl-10,15,20-triphenylpor
-phyrinato gold(III) chloride], a gold(III) porphyrin 
analogue, suppresses proliferation in a panel of 
human breast cancer cells and exhibits potent 
anti-tumor activity in nude mice implanted or-
thotopically with human breast cancer MDA-MB-
231 cells [12]. The cytotoxicity of gold-2a is 
~3,000-fold higher than cisplatin. Moreover, 
these two drugs exert their anti-tumor activities 
through completely different mechanisms. Gold-
2a acts as a histone deacetylase inhibitor 
(HDACi) and selectively blocks Wnt/β-catenin 
signaling at the transcriptional level [12]. The 
present study was designed to further investi-
gate the molecular mechanisms underlying gold
-2a-mediated inhibition of WNT1 gene expres-
sion. The transcription factor YY1 was shown to 
interact with a gold-2a response element of the 
WNT1 promoter and to recruit a repressor com-
plex for suppressing WNT1 gene expression. 
Gold-2a treatment blocked YY1 shuttling to the 
cytosol and promoted its nuclear accumulation, 
which in turn arrested cell cycle in the G1/S 
phase. In addition, gold-2a selectively elimi-
nated HDAC3 from the YY1-containing protein 
complex and promoted its cytosol translocation.  
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Abstract: The gold (III) porphyrin complex, gold-2a, elicits anti-tumor activity by targeting the Wnt/β-catenin signaling 
pathway [Chow KH et al, Cancer Research 2010;70(1):329-37]. Here, the molecular mechanisms underlying the 
inhibitory effects of this compound on WNT1 gene expression were elucidated further. A response element to gold-2a 
was identified located within the -1290 to -1112 nt region of the WNT1 promoter, containing a binding site for the 
transcription regulator Yin Yang 1 (YY1). Gold-2a promoted the association of YY1 and suppressor of zeste 12 
(Suz12; a component of the polycomb repressor complex 2) with the WNT1 promoter. Under normal culture condi-
tions, the intracellular translocalization of YY1 was synchronized with cell cycle progression and WNT1 expression. 
Gold-2a promoted the nuclear accumulation and abolished the nuclear exportation of YY1, resulting in a persistent 
inhibition of WNT1 expression and a cell cycle arrest at G1/S phase. A dimorphic role of YY1 in regulating cell prolif-
eration and division was revealed. Thus, the present study extends the understanding of the anti-tumor mechanism 
of gold-2a to the epigenetic level, which involves the modulation of the dynamic interactions between YY1 and a spe-
cific region of the WNT1 promoter.  
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Materials and methods 
 
Antibodies and reagents 
 
Antibodies against Suz12 and beta-actin were 
obtained from Cell Signaling (Beverly, MA, USA). 
Antibodies against HDAC1, HDAC3, HDAC8 and 
YY1 were obtained from Santa Cruz Biotechnol-
ogy Inc. (Santa Cruz, CA, USA). SYBR® Green-
ERTM qPCR Supermix, LipofectamineTM transfec-
tion reagent, TRIzol®, pcDNA3.1+ vector, DAB 
substrate kit and ProLong® Gold antifade re-
agent with DAPI were from Invitrogen (Carlsbad, 
CA, USA). iProof high fidelity PCR kit was from 
Bio-Rad Laboratories (Hercules, CA, USA). The 
firefly-luciferase pGL3-basic vector, ImProm-IITM 
reverse transcription System, and Bright-GloTM 
luciferase assay system were from Promega 
(Madison, WI, USA). QIAquick gel extraction kit 
and T4 DNA ligase were from Qiagen (Hilden, 
Germany). The BCA Protein Reagent Kit was 
from Pierce (Rockford, IL, USA). The complete 
protease inhibitor cocktail was from Roche Ap-
plied Science (Mannheim. Germany). The hu-
man breast carcinoma MDA-MB-231 cell lines 
were obtained from American Type Culture Col-
lection on December 2004. The identities of 
these cells were confirmed by STR-profiling us-
ing the Cell ID System from Promega (last 
tested on 18/01/10). The synthesis of the gold
(III) porphyrin complex (gold-2a) and the ele-
mental analyses were conducted as described 
[12]. Gold-2a was dissolved in dimethyl sulfox-
ide (DMSO) and further diluted with phosphate 
buffered saline (PBS). A concentration of 0.1 μM 
gold-2a was used for all experiments of the pre-
sent study.  
 
Quantitative reverse transcription-PCR and 
chromatin immunoprecipitation-PCR 
 
Quantitative reverse transcription-PCR (QPCR) 
was performed as described [12]. All reactions 
were analyzed using the melting curve to ensure 
the specificity of the real-time PCR reaction. The 
QPCR primers for human WNT1 (NM_ 
005430.2) were forward 5’-GCA GCG ACA ACA 
TTG ACT TC-3’and reverse 5’-GTG GCA CTT GCA 
CTC CTG-3’. The procedure of chromatin im-
munoprecipitation (ChIP)-PCR has been de-
scribed [12]. PCR amplifications were per-
formed using 10% of the chromatin samples, 
and the resulting products were quantified by 
both densitometry (MultiAnalyst Software, Bio-
Rad) and QPCR analysis. For determination of 
gene expression, values obtained were normal-
ized to those of the internal control 18S RNA. 
For promoter analysis by ChIP-PCR, values ob-
tained were normalized against those of the 
corresponding input samples before immuno-
precipitation. The primers used are listed in 
Supplementary Table S1. 
 
Construction of reporter vectors for promoter 
activity analysis 
 
The human WNT1 promoter sequences were 
amplified using the genomic DNA template de-
rived from MDA-MB-231 cells. Primers used for 
different promoter regions are listed in Supple-
mentary Table S2. The PCR products (digested 
with restriction enzymes XhoI and HindIII) were 
cloned into the pGL3-basic vector. The inserts 
were confirmed by DNA sequencing. To analyze 
the transcription activities of WNT1 promoter, 
the reporter vectors were transfected transiently 
into MDA-MB-231 cells and the luciferase activ-
ity was measured using cell lysates as de-
scribed [17]. All values were normalized to the 
control Renilla luciferase signals. The cloning 
primers are listed in Supplementary Table S2. 
 
Construction of YY1 mammalian expression 
vector 
 
RNA was extracted from MDA-MB-231 cells using 
TRIzol® reagent according to the manufacturer’s 
instructions. One microgram of total RNA was 
used for the synthesis of first strand cDNA using 
the ImProm-IITM Reverse Transcription System. 
The primers for cloning human YY1 gene were 5’-
CTG CGG ATC CAT GGA CTA CAA GGA TGA CGA 
TGA CAA GAG CCA TGG CCT CGG GCG A-
3’ (forward) and 5’-CTG CCT CGA GCT ACT GGT 
TGT TTT TGG CCT TAG CAT GTG-3’(reverse). The 
restriction enzymes (BamHI and XhoI)-digested 
PCR fragments were cloned into a pcDNA3.1+ 
vector to generate the mammalian expression 
vector pcDNA-YY1, which encoded an NH2-
terminus FLAG-tagged human YY1.  
 
siRNA knocking down of YY1  expressions 
 
Three sets of YY1 siRNAs were obtained from 
Fulengen Co. (Guangzhou, China) for suppress-
ing YY1 expression in MDA-MB-231 cells. The 
siRNA sequences are listed in Supplementary 
Table S3. Ten microliters of 20 µM siRNA mix-
ture or scramble siRNA control were introduced 
into the cells using LipofectamineTM 2000 trans-
fection reagent. The down-regulations of YY1 
were confirmed by Western blotting and QPCR 
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analysis. 
 
Cell proliferation and [3H] thymidine incorpora-
tion assays 
 
Cells were seeded at a density of 2 x 104 cells / 
well in 24-well plates. Transient transfection 
was performed for overexpression or downregu-
lation of YY1. After fasting for 24 hours, 10% 
FBS was added into the culture. Radio-labeling 
was performed by adding 1 µCi/ml of [3H-
methyl]-thymidine into the culture for the last six 
hours. At the end of the experimental period, 
the number of viable cells was counted manu-
ally by mixing with trypan blue dye. The protein 
amounts were quantified with a BCA protein 
assay (Pierce). For radiolabeled cells, after 
washing and trichloroacetic acid precipitation, 
DNA was solubilized with 0.2 M NaOH, neutral-
ised with 0.2 M HCl and the radioactivity was 
quantified with a liquid scintillation counter.  
 
Cell cycle analysis 
 
Cells fixed with 70% ethanol were resuspended 
in staining buffer [100 mM Tris, pH 7.4, 150 
mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, 0.1% NP-
40 and 2 mg/ml propidium iodide] and incu-
bated in the dark for 20 minutes on ice. The 
analysis was carried out with an EPICS® Elite 
ESP Flow Cytometer and EXPO software 
(Beckman Coulter, Miami, FL, USA). Data was 
acquired from 1 x 105 cells per sample and gat-
ing of G1/S, S, and G2/M populations was sub-
sequently performed manually using WinList 
software (Purdue University Cytometry Laborato-
ries, West Lafayette, IN, USA).  
 
Subcellular fractionation and Western blotting 
 
Cells were resuspended in a hypotonic buffer 
(10 mM Tris-HCl, pH 7.5, 25 mM KCl, 2 mM Mg 
acetate, 1 mM DTT, 0.5 mM PMSF and protease 
inhibitor cocktails). After incubating on ice for 
ten minutes, cell membranes were disrupted by 
passing through a 23-gauge needle and nuclear 
isolation was monitored under a light micro-
scope. After centrifugation for five minutes at 
1000 x g, the supernatant was saved as 
“cytoplasmic fraction”. The nuclear pellet was 
washed once with the hypotonic buffer and 
lysed with hypertonic buffer (hypotonic buffer 
plus 400 mM KCl and 20% glycerol). The lysates 
were then centrifuged at 12,000 x g for five min-
utes, and the supernatant was collected as 
“nuclear fraction”. Protein concentrations were 
determined by the BCA method. Total cell lys-
ates, cytoplasmic or nuclear fractions were 
separated by SDS-PAGE, transferred to PVDF 
membranes and then probed with various pri-
mary antibodies. The antibody-antigen com-
plexes were detected using an enhanced 
chemiluminescence kit from GE Healthcare 
(Uppsala, Sweden).  
 
Co-immunoprecipitation 
 
Total cell lysates were prepared by homogeniza-
tion in RIPA buffer [50mM Tris-HCl, pH 7.4; 1 
mM EDTA; 150 mM NaCl; 1 % Nonidel P40; 1 % 
Triton X-100; 0.5 % deoxycholic acid sodium 
salt; 1 mM NaF; 1 mM sodium orthovanadate; 
and a complete protease inhibitor cocktail] on 
ice and centrifuged for ten minutes at 12,000 x 
g to remove any large debris. The protein con-
centration of the supernatant was determined 
with a BCA Protein Reagent Kit. Five hundred 
micrograms of the total cell lysates were incu-
bated with non-immune rabbit IgG and pre-
cleared with 50 μl of protein G-Sepharose 
beads, and then incubated with two micrograms 
of antibody overnight at 4oC. Fifty microliter of 
protein G-Sepharose beads were added and the 
incubation was prolonged for another two 
hours. The beads-bound immune complexes 
were collected by centrifugation, washed twice, 
and eluted into a buffer containing 0.2 M Gly-
cine-HCl, pH 2.5. After neutralization, the 
eluants were subjected to SDS-PAGE and West-
ern blotting analysis. 
 
Immunocytochemical staining 
 
Transient transfection was performed in MDA-
MB-231 cells seeded on cover slips. After 
methanol fixation, cells were blocked with 5% 
FBS in TBS-T buffer (0.1 % Triton X-100, 0.15 M 
NaCl, 0.05 M Tris-HCl, pH7.4) for one hour and 
incubated overnight with different antibodies at 
4°C. The cells were subsequently washed with 
TBST and incubated with anti-mouse Alexofluor 
(Invitrogen) for one hour at room temperature in 
the dark. ProLong® Gold antifade reagent was 
used as the mounting medium. Signals were 
detected and images were captured using a 
fluorescent microscope (Leica Microsystems, 
Bensheim, Germany).  
 
Data analysis and statistics 
 
All experiments were performed with three to six 
samples per group, and results were derived 
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from at least three independent experiments. 
Data are shown as mean values ± SD. Unless 
otherwise specified, comparison between 
groups was done using Student's paired t test. P 
values less than 0.05 were considered to indi-
cate statistically significant differences. 
 
Results 
 
Gold-2a inhibited WNT1 promoter activity in 
MDA-MB-231 cells 
 
Previous study revealed that treatment with 
gold-2a blocked the gene expression of WNT1 in 
MDA-MB-231 cells [12]. To further delineate the 
underlying mechanisms, luciferase reporters of 
WNT1 promoter were constructed by inserting 
fragments of various lengths within the 1.5 kb 
region upstream of the ATG initiation codon into 
a pGL3-Basic vector (Figure 1A). Transient 
transfection was performed in MDA-MB-231 
cells to test the activity of these WNT1 promoter 
reporters. In cells cultured under both serum 
free and serum containing conditions, the pro-
moter activities of pGL3-WNT1 (-1290 to -1) and 
pGL3-WNT1 (-1415 to -1) were consistently 
lower than those of pGL3-WNT1(-1503 to -1) 
and pGL3-WNT1(-1112 to -1). Compared to se-
rum free cultures, incubation with 10 % FBS 
significantly elevated the luciferase signal in 
cells transfected with pGL3-WNT1(-1290 to -1) 
and pGL3-WNT1(-1415 to -1) (Figure 1B). By 
contrast, serum had no stimulatory effects on 
the promoter activity of pGL3-WNT1 (-1112 to -
1) and pGL3-WNT1(-1503 to -1). In cells ex-
posed to gold-2a, as early as two hours after 
adding the compound, the activities of WNT1 
promoters covering the regions of -1290 to -1 nt 
and -1415 to -1 nt were significantly reduced by 
approximately 50 to 70% compared to vehicle 
controls, in both serum free and serum contain-
ing conditions (Figure 1C). In addition, gold-2a 
attenuated the activity of pGL3-WNT1(-1503 to -
1) by approximately 20 to 40%. These results 
suggest that the region between -1290 to -1112 
nt of the WNT1 promoter contains regulatory 
elements responsible for both serum-mediated 
activation and gold-2a-induced inhibition of 
WNT1 expression. 
 
Gold-2a facilitated the associations of YY1 and 
Suz12 with the WNT1 promoter 
 
In mouse embryonal cells, the 1.5 kb Wnt1 pro-
moter upstream of the ATG site is the target of 
Suz12, a major component of the Polycomb 
Repressive Complex 2 (PRC2) [18]. Similar as-
sociation of Suz12 has been demonstrated to 
Figure 1. Gold-2a inhibits WNT1 promoter activity in 
MDA-MB-231 cells. A, Four luciferase reporters of 
WNT1 promoter were constructed into the pGL3-
Basic vector containing the upstream 1.5 kb se-
quences with different lengths. B, The reporter activ-
ity was tested by transient transfection of these plas-
mids into MDA-MB-231 cells. Luciferase signals were 
measured as described in Methods and the values 
normalized to the control Renilla luciferase signal. *, 
P < 0.05 versus samples cultured under serum-free 
conditions (n = 5). C, Two hours of gold-2a treatment 
resulted in significant inhibition of WNT1 promoter 
activity. The data were calculated as percentage 
inhibition of that detected in vehicle-treated sam-
ples.  
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occur at the same region of 
the WNT1 promoter in 
SW480 human colon cancer 
cells [19]. YY1 is a transcrip-
tion regulator physically in-
teracting with Suz12 and 
acting as a mediator to re-
cruit the polycomb group 
proteins to participate in the 
gene silencing process [20]. 
I n  s i l i c o  p r e d i c t i o n 
(MatInspector v2.2 program 
[21], JASPAR [22], and 
TFSEARCH [23]) suggested 
that there were in total six 
YY1 binding sites (CCAT) 
within the human WNT1 
promoter (Figure 2A). Four 
of them resided within the 
region between -1503 to -
1112 nt upstream of ATG 
site. Among these, the 
“CCAT” located between -
1290 and -1112 nt (-1265/-
1262) was conserved in 
both mouse and human 
WNT1 gene promoters 
(Figure 2B).  
 
Next, the potential ability of 
gold-2a to modulate the 
binding of Suz12 and YY1 to 
WNT1 promoter was exam-
ined. Four sets of primers 
covering different regions of 
the 1.5kb fragment were 
designed and used for ChIP-
PCR experiments (Figure 3A 
and Supplementary Table 
S2). Gold-2a significantly 
elevated the amount of 
these two transcriptional 
regulators bound to the 
WNT1 promoter (by approxi-
mately18 and 30 folds, for 
Suz12 and YY1, respec-
tively), mainly at the region 
covered by primer 3 (Figure 
3B). The promoter associa-
tions of the three class I 
HDACs were also evaluated. 
Gold-2a treatment de-
creased the amounts of 
HDAC3 at all four tested 
regions of the WNT1 pro-
Figure 2. In silico analysis of YY1 binding motifs of the WNT1 promoter.  A, A 
schematic illustration of the locations of potential YY1 binding sites within the 
1.5 kb upstream of the WNT1 promoter and the promoter reporters. B, Homol-
ogy comparison of human and murine WNT1 promoters. 
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moter. The highest inhibition was detected by 
ChIP-PCR using primer 3 (-1356 to -1113 nt).  
 
The protein-protein interaction between YY1 and 
Suz12 was evaluated by co-immunoprecipi-
tation in cells treated with or without the drug 
compound. Gold-2a significantly increased the 
amount of Suz12 bound to YY1. By contrast, a 
significant reduction of HDAC3 in the immuno-
complex was observed in cells treated with gold-
2a (Figure 3C), whereas the interactions of 
HDAC1 and HDAC8 with YY1 were not signifi-
cantly affected.  
 
Taken in conjunction, these findings suggested 
that gold-2a promoted the binding of a tran-
scription repressor complex containing YY1 and 
Suz12 to a DNA element located within the re-
gion of -1356 to -1113 of the WNT1 promoter.  
 
YY1 acted as a negative regulator of WNT1 
expression in MDA-MB-231 cells 
 
To confirm the role of YY1 in regulating WNT1 
gene expression, a mammalian expression vec-
tor (pcDNA-YY1) encoding a NH2-terminal Flag-
tagged YY1 was constructed. In addition, a spe-
cific siRNA was designed for downregulation of 
YY1 expression. Compared to the starved MDA-
MB-231 cells, serum treatment had no signifi-
cant effect on the mRNA levels of YY1, but ele-
vated those of WNT1 by approximately 13 folds 
(Figure 4A). Overexpression of YY1 by transient 
transfection of pcDNA-YY1 vector almost abol-
ished the serum-stimulated WNT1 expression, 
at both gene and protein levels, whereas knock-
ing down of YY1 (by approximately 70%) led to a 
30 to 40 folds increase of WNT1 mRNA and 
protein expression levels (Figure 4B). To locate 
the exact region of WNT1 promoter regulated by 
YY1, MDA-MB-231 cells were transfected with 
either pcDNA-YY1 vector or YY1 siRNA, together 
with different pGL3-WNT1 reporters. Except for 
those driven by pGL3-WNT1(-1112 to -1), over-
expression of YY1  significantly inhibited the 
other three WNT1 promoter fragments-
mediated reporter activities (Figure 4C). Knock-
ing down of YY1 elevated the reporter activities 
of both pGL3-WNT1(-1290 to -1) and pGL3-
WNT1(-1415 to -1). Moreover, the association 
Figure 3. Gold-2a differentially regulates the associations of HDAC3, YY1 and Suz12 with the WNT1 promoter. A, Four 
sets of primers were designed for ChIP-PCR covering different regions of the WNT1 promoter. B, Serum-starved MDA-
MB-231 cells were subjected to gold-2a treatment for two hours. Quantitative ChIP-PCR analysis was performed using 
specific antibodies against HDAC1, HDAC3, HDAC8, YY1, and Suz12 as described in Methods. Results were pre-
sented as fold changes compared to corresponding vehicle control groups. *, P < 0.05 versus vehicle control of the 
same primer set (n = 3). C, YY1 was immunoprecipitated from the cells treated with or without gold-2a. The amounts 
of HDAC1, HDAC3, HDAC8, YY1, and Suz12 were monitored by Western blotting.  
Gold-2a and WNT1 gene regulation  
 
 
485                                                                                                              Am J Transl Res 2011;3(5):479-491 
of Suz12 with WNT1 promoter appeared to be 
regulated by YY1. ChIP-PCR analysis revealed 
that the most significant changes were ob-
served at -1356 to -1113 nt of the WNT1 pro-
moter (covered by primer 3), which contained 
only one YY1 binding motif (-1265/-1262). The 
amount of Suz12 bound to this region was sig-
nificantly increased (over four fold) in cells over-
expressing YY1 and reduced (by approximately 
70%) in those transfected with YY1 siRNA 
(Figure 4D). In summary, these data indicated 
that YY1 was able to recruit the polycomb group 
protein Suz12 to a specific region of WNT1 pro-
moter, resulting in transcriptional repression.  
  
Serum-induced nucleocytoplasmic shuttling of 
YY1 was blocked by gold-2a treatment 
 
It has been reported previously that YY1 shut-
tles between cytosol and the nucleus [24]. Here, 
in MDA-MB-231 cells, at as early as two hours 
after FBS-stimulated cell cycle release, YY1 was 
exported from the nucleus into the cytosol 
(Figure 5A). At 12 hours, when cells almost com-
pleted G2/M phase and prior to the start of an-
other cycle, YY1 was shuttled back into the nu-
clei (Figure 5B). An oscillation of WNT1 gene 
and protein expression was observed to syn-
chronize the translocation of YY1 between nu-
cleus and cytosol (Figure 5C). HDAC3 was also 
actively shuttling between nucleus and cytosol 
during cell cycle progression, but in a manner 
opposite to that of YY1 (Figure 5A). Gold-2a 
blocked YY1 shuttling to the cytosol and pro-
moted its nuclear accumulation (Figure 5A), 
which was accompanied by an arrested cell cy-
cle progression at G1/S phase (Figure 5B). 
Compared to the vehicle control group, the aver-
age numbers of cells in G2/M phase were re-
duced by approximately two to six folds after 12 
Figure 4. YY1 represses WNT1 promoter activity in MDA-MB-231 cells. Transient transfection was performed for up- 
or down-regulation of YY1 expression. Twenty four hours after transfection, the mRNA (A) and protein (B) levels of YY1 
and WNT1 were quantified by QPCR and Western blotting, respectively. The promoter activity was evaluated as de-
scribed in Methods by co-transfection with the four different WNT1 promoter reporters (C). The association of Suz12 
with WNT1 promoter was evaluated by quantitative ChIP-PCR and the results expressed as fold changes against the 
pcDNA group of the same primer set (D). *, P < 0.05 versus pcDNA group; #, P < 0.05 versus scramble RNA group 
(n=5).  
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hours of drug treatment. The oscillation of 
HDAC3 between cytosol and nucleus was also 
abolished in cells treated with gold-2a. In con-
trast to YY1, the nuclear HDAC3 contents were 
decreased, whereas the cytosol HDAC3 levels 
were elevated by gold-2a. Moreover, WNT1 ex-
pression, at both the mRNA and protein levels, 
could no longer be stimulated by serum and did 
not exhibit cell cycle-dependent oscillations 
(Figure 5, A and B). These results suggested 
that gold-2a elicited its anti-proliferative actions 
in part by blocking YY1 transportation from the 
nucleus to the cytoplasm, thus enhancing its 
nuclear accumulation, which in turn resulted in 
a constant inhibition of WNT1 gene expression 
and cell cycle progression.  
Gold-2a and YY1 elicited simi-
lar anti-proliferative effects by 
promoting cell cycle arrest at 
G1/S phase 
 
To extend the understanding of the role 
of YY1 on cell cycle progression, MDA-
MB-231 cells with over- or reduced 
expression of YY1 were subjected to 
flow cytometry analysis (Figure 6). 
Upregulation of YY1 resulted in an in-
creased number of cells in the G1/S 
phase, whereas downregulation of this 
protein elevated the mitotic cell popu-
lations in the G2/M phase and pro-
moted cell cycle progression towards 
the post-G2/M phase [i.e. cells with a 
chromosome number of more than 
4N]. Morphologically, a large portion of 
cells transfected with YY1 siRNA exhib-
ited aneuploidy, as indicated by the presence of 
multiple nuclei. By contrast, cells overexpress-
ing YY1 were enlarged with mononuclear (Figure 
7A). Gold-2a elicited similar effects as YY1 in 
arresting the cell cycle at the G1/S phase 
(Figure 6). Cells treated with the drug showed a 
single enlarged nucleus and a spreading cyto-
plasm with YY1 mainly localized within the nu-
cleus (Figure 7A). Cell proliferation analysis re-
vealed that while both overexpression and 
downregulation of YY1 decreased the number of 
cells, their effects on DNA synthesis were oppo-
site (Figure 7B). In general, knocking down of 
YY1 in MDA-MB-231 cells promoted DNA and 
protein synthesis. By contrast, gold-2a and YY1 
upregulation reduced the total amount of DNA 
Figure 5. Gold-2a treatment arrests cell 
cycle progression at G1/S phase and abol-
ishes nucleocytoplasmic shuttling of YY1 
and HDAC3. MDA-MB-231 cells were serum 
starved for 24 hours prior to serum (10% 
FBS) stimulation in the presence or ab-
sence of gold-2a. At different time points, 
cells were harvested for nuclear and cytosol 
fractionation and Western blotting (A), cell 
cycle analysis (B) and QPCR analysis of 
WNT1 gene expressions (C). Note that the 
cell cycle-dependent oscillation of WNT1 
mRNA expression was abolished by gold-
2a. The results were calculated as fold 
changes over the values at time zero. 
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per cell. The suppressive effects of gold-2a on 
DNA synthesis and cell proliferation were more 
prominent than those of YY1. These results 
demonstrated that YY1 might play a dual role in 
both DNA synthesis and cytokinesis. Gold-2a 
exerted the cytotoxic activity at least in part by 
enhancing the action of YY1, which in turn 
blocked DNA synthesis and prevented subse-
quent mitosis.  
 
Discussion 
 
WNT signaling is essential for the normal devel-
opment of multi-cellular organisms and pertur-
bations in the canonical Wnt/β-catenin pathway 
play an important role in the genesis of various 
cancers, including breast, colon, liver, and lung 
tumors [25]. Since the discovery of INT1/Wnt1 
in 1982 [26], limited information is available 
regarding the transcriptional regulation of hu-
man WNT1 gene expressions. Most studies 
have focused on murine Wnt1 gene expression 
[18, 27-35]. In undifferentiated mouse embry-
onic PC19 cells, Wnt1 expression can be trig-
gered by retinoic acid [36]. A 128 bp (-370 to -
347) of the 5’ upstream region of Wnt1 pro-
moter is responsible for this retinoic acid-
mediated transcription [34]. Paired box-3, a 
transcriptional factor that is essential for normal 
development of the somatic mesoderm, has 
been identified to interact with the -330 to -326 
binding site and induce transcriptional activa-
tion of Wnt1 [29]. Several repressors of Wnt1 
expression have been described [18, 30, 31]. 
Sine oculis-related homeobox-3 homolog (Six3) 
suppresses Wnt1 expression in mice embryos 
by binding to an unknown sequence at the 3’ 
end of its coding region as well as to the ele-
ments located within the 5’ promoter region (-
1546 to -1518; and -1294 to -1266) [31]. Wnt1 
is also a target gene for the polycomb group-2 
complex (PRC2), composed of histone methyl-
transferase Enhancer of Zeste protein-2 (Ezh2), 
Extra Sex Combs protein (Eed) and Suppressor 
of Zeste-12 (Suz12). In F9 mouse embryonic 
teratocarcinoma cells, both Ezh2 and Suz12 
bind to a region within the 1.5 kb upstream of 
the transcription starting site of the Wnt1 pro-
moter to inactivate gene transcription [18]. An 
association of Suz12 within the -1000 to -2000 
upstream region of WNT1 promoter has been 
demonstrated in SW480 human colon cancer 
cell, MCF-7 human mammary carcinoma cells, 
and Ntera2 human embryonic carcinoma cells 
[18, 19].  
 
The present study demonstrates that overex-
pression of YY1 decreases, whereas knocking 
down of YY1 elevates WNT1 gene expression. 
YY1 is able to recruit a repressor complex con-
taining Suz12 to the WNT1 promoter and sup-
press its gene expression. At the cellular level, 
as in previous findings [37], a dual role of YY1 in 
regulating cell cycle progression and cytokinesis 
has been observed. Downregulation of YY1 re-
sults in cytokinetic failure and genomic instabil-
Figure 6. Modulation of YY1 expression alters 
cell cycle progression. Transient transfection 
was performed as in Figure 4. After 24-hour 
fasting, cells were cultured for another 48 
hours in media containing 10% FBS prior to 
flow cytometry analysis as described in Meth-
ods. Compared to control MDA-MB-231 cells 
(A), overexpression of YY1 elevated the number 
of cells at G1/S phase and decreased those at 
G2/M phase (B), whereas down-regulation of 
YY1 by siRNA promoted the cell cycle progres-
sion to G2/M phase (C). Gold-2a treatment 
elicited similar effects as those of YY1 over-
expressed cells (C). Note that similar results 
were obtained for cells exposed to vehicle (A) 
or transfected with pcDNA or scramble RNA 
(data not shown). Populations of cells with 
chromosome >4N (aneuploidy) are indicated 
by arrow (C). 
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ity, while activation of YY1 promotes cell cycle 
arrest at the G1/S phase. These results are in 
line with the evidence that aberrant activation 
of Wnt/β-catenin signaling can induce chromo-
somal instability [38-40]. Several downstream 
target genes, including conductin/axin2, APC, 
beta-catenin/TCF, are implicated in causing 
chromosomal instability and loss of mitotic 
checkpoint control [39, 41, 42]. Based on these 
facts, it seems reasonable to propose that YY1 
acts as an upstream regulator for the opti-
mal control of WNT1 expression during 
normal cell cycle progression, and that dys-
regulated YY1 function contributes to the 
aberrant activation of Wnt signaling, in turn 
leading to transformation and development 
of tumors.  
 
YY1 plays a fundamental role in various 
biological processes [including embryo-
genesis, differentiation, development and 
tumorigenesis] by interacting with several 
other factors to initiate, activate or repress 
transcription [43, 44]. The majority of the 
clinical data show that YY1 is over-
expressed in tumor tissues and may affect 
tumor behavior [45]. In human breast tu-
mors, YY1 positively correlates with the 
expression of both ERBB2/HER2 and oes-
trogen receptors [46, 47]. However, the 
prognostic value of these associations is 
not conclusive. Reduced YY1 expression 
may contribute to the invasive phenotype 
of breast cancer cells due to impaired epi-
genetic silencing [48]. Whether or not an 
actual association exists between YY1 and 
WNT1 expression in human breast tumors 
is unknown. Several lines of evidence sup-
port the role of YY1 in the occurrence of 
chemoresistance. Thus, YY1 inhibition sen-
sitizes lymphoma B-NHL cells to Fas-
induced apoptosis [49]. In prostate carci-
noma PC-3 cells, downregulation of YY1 
enhances TRAIL-mediated apoptosis [50]. 
In ovarian cancer patients, YY1 function is 
positively correlated with survival of pa-
tients treated with paclitaxel. Moreover, 
increased sensitivity to taxanes is found in 
NCI60 cancer cell lines with a high YY1 
expression [51]. The effects of YY1 in 
modulating chemosensitivity of breast can-
cer cells have not been reported.  
 
The gold (III) porphyrin complex, gold-2a, is 
a newly discovered cytotoxic drug com-
pound showing potent anti-tumor activity 
against breast cancer [12]. It acts as a HDACi to 
modulate the gene expression in the canonical 
Wnt signaling pathway. The present study dem-
onstrates that gold-2a inhibits WNT1 promoter 
activity at least in part by promoting the binding 
of the YY1 repressor complex to a specific re-
gion containing a conserved YY1 motif (“CCAT” 
located at -1265/-1262). Apparently, the regu-
latory elements responsible for serum-mediated 
activation of WNT1 gene expression are also 
Figure 7. Cytokinesis defects and nuclear abnormalities in-
duced by alterations of YY1 expression. Transfection and drug 
treatment were performed as in Figure 6. A, Nuclear morpholo-
gies and YY1 contents were analyzed by fluorescent micros-
copy. More than one nucleus (polyploidy) was observed in cells 
with reduced YY1 expression. Representative images are 
shown (Magnification, 400x). Note that similar results were 
obtained for cells treated with vehicle, or transfected with 
pcDNA or scramble RNA. B, Cell number, protein and DNA 
contents were analyzed as described in Methods. *, P < 0.05 
versus pcDNA group; #, P < 0.05 versus scramble RNA group; 
&, P < 0.05 versus vehicle controls (n=5).  
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located within the same region. However, the 
activity of gold-2a is not affected by the pres-
ence of serum. The regulation of YY1 has not 
been fully elucidated. Both histone acetyltrans-
ferases [e.g. P300 and CREB-binding protein] 
and HDACs, [HDAC1, 2, and 3] can interact with 
YY1 [44, 52]. YY1 activity can be regulated by 
acetylation and deacetylation. The co-
immunoprecipitation experiments of the present 
study confirm the association of class I HDACs 
with YY1 in MDA-MB-231 cells. Interestingly, 
gold-2a selectively blocked the association of 
HDAC3 with the WNT1 promoter and eliminated 
HDAC3 from the YY1-containing protein com-
plex. Moreover, the sub-cellular distribution pat-
terns of YY1 and HDAC3 changed in opposite 
directions during the cell cycle progression. YY1 
located mainly in the nucleus in the G1/S phase 
but shuttled to the cytoplasm during the G2/M 
phase, whereas HDAC3 was translocated from 
nucleus to cytosol at the G1/S boundary. The 
shuttling events coincided with the oscillations 
in WNT1 expression. Gold-2a treatment induced 
G1/S phase cell cycle arrest and prevented the 
nucleo-cytoplasmic shuttling of both YY1 and 
HDAC3. These findings indicate a potential 
mechanism of protein/protein interactions and 
post-translational modifications involved in the 
modulation of YY1 functions by gold-2a.  
 
In summary, the results of the present study 
suggest that YY1 is a transcriptional repressor 
and mediates the inhibitory effects of gold-2a 
on WNT1 gene expression. Gold-2a exerts its 
anti-proliferative and cell cycle arresting effects 
at least in part by blocking the intracellular 
translocation of YY1. Considering the potential 
role of YY1 in tumor cell resistance to chemot-
herapeutics, the present findings shed new 
lights on the potential development of gold-2a 
as an anti-cancer compound for clinical use.  
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Supporting Information 
Supplementary Table S1. Primers used for ChIP-PCR. 
Gene Promoter region Sequences 
WNT1 
(NC_000012.11) 
 
-1567-1045 (F): 5’-TGT GGT GGG AAC TAG AGC TT-3’ 
(R): 5’-TGC GGA TGT CCA CTG TAT GT-3’ 
-1418-1267 (F): 5’-AGT GGA CAT CCG CAC CAT-3’ 
(R): 5’- TGT CAC ACT GTG GTA TGT GTC AA-3’ 
-1356-1163 (F): 5’-AGG CTG GGT TCA CCT CAA TA-3’ 
(R): 5’-CTG GAC TGT GTG TGG AGT GG-3’ 
-839-627 (F):5’-AGC AAA CTG CCT GTT GCT TT-3’ 
(R): 5’-GAG TGT CGG AAG GAA AGC TG-3’ 
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Supplementary Table S2. Sequences of primers used for constructing the WNT1 promoter reporters 
and the YY1 expression vector 
 
Vectors Cloning primers 
pGL3-WNT1 
(-1503 to -1) 
(F): 5’-CTG CCT CGA GCA CAT GGA GGC ACA AGT TTC -3’ 
(R): 5’- CTG CAA GCT TGG CCT GCC TGG CTT TGC C-3’ 
pGL3-WNT1 
(-1415 to -1) 
(F): 5’-CTG CCT CGA GGA CAT CCG CAC CAT TTC CCA T -3’ 
(R): 5’- CTG CAA GCT TGG CCT GCC TGG CTT TGC C-3’ 
pGL3-WNT1 
(-1290 to -1) 
(F): 5’-CTG CCT CGA GCA CAT ACC ACA GTG TGA CAC GCC -3’ 
(R): 5’- CTG CAA GCT TGG CCT GCC TGG CTT TGC C-3’ 
pGL3-WNT1 
(-1112 to -1) 
(F): 5’-CTG CCT CGA GCC TCC TTC CTG ACA CAC TGC CC -3’ 
(R): 5’- CTG CAA GCT TGG CCT GCC TGG CTT TGC C-3’ 
pcDNA-YY1 (F): 5-CTG CGG ATC CAT GGA CTA CAA GGA TGA CGA TGA CAA GAG CCA TGG CCT 
CGG GCG A-3’ 
(R): 5-CTG CCT CGA GCT ACT GGT TGT TTT TGG CCT TAG CAT GTG-3’ 
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Supplementary Table S3. Sequences of RNA interference oligos 
Gene Sequences  
YY1 (NM_003403) (F): 5'  CGACGACUACAUUGAACAA dTdT 3' 
(R):3' dTdT GCUGCUGAUGUAACUUGUU  5' 
(F): 5'  CAAAGAUGUUCAGGGAUAA dTdT 3 
(R): 3' dTdT GUUUCUACAAGUCCCUAUU  5' 
(F): 5'  CCUGAAAUCUCACAUCUUA dTdT 3' 
(R): 3' dTdT GGACUUUAGAGUGUAGAAU  5' 
Scramble RNA control (F): 5’ GAUACACGAAGGAAUUCACUUCUAA 3’ 
(R): 5’ UUAGAAGUGAAUUCCUUCGUGUAUC 3’ 
 
 
 
 
 
 
 
 
 
 
 
  
